Anupam Rasayan India Ltd (BOM:543275)

India · Delayed Price · Currency is INR

1,151.45

+21.05 (1.86%)

At close: Oct 28, 2026

Market Cap	131.08B +5.5%
Revenue (ttm)	25.35B +51.9%
Net Income	1.75B +41.5%
EPS	15.11 +34.8%
Shares Out	n/a
PE Ratio	76.18
Forward PE	40.11
Dividend	1.50 (0.13%)
Ex-Dividend Date	Sep 18, 2026

Volume	2,155
Open	1,121.75
Previous Close	1,130.40
Day's Range	1,121.75 - 1,157.10
52-Week Range	1,053.45 - 1,415.40
Beta	n/a
Analysts	Hold
Price Target	1,279.17 (+11.09%)
Est. Earnings	Nov 13, 2026

About Anupam Rasayan India

Anupam Rasayan India Ltd engages in the custom synthesis and manufacturing of specialty chemicals in India, Europe, Japan, Singapore, China, North America, and internationally. It operates through two segments, Life Science related Specialty Chemicals and Performance Material. The company offers life science related specialty chemicals, such as agro intermediates and agro active ingredients for the agrochemicals industry; anti-bacterial and ultraviolet protection intermediates and ingredients for the personal care industry; and intermediates an... [Read more]

Industry Specialty Chemicals

Sector Materials

Founded 1984

Employees 2,501

Stock Exchange Bombay Stock Exchange

Ticker Symbol 543275

Full Company Profile

Financial Performance

In fiscal year 2026, Anupam Rasayan India's revenue was 23.65 billion, an increase of 64.61% compared to the previous year's 14.37 billion. Earnings were 1.70 billion, an increase of 82.24%.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for 543275 stock is "Hold." The 12-month stock price target is ₹1,279, which is an increase of 11.09% from the latest price.

Price Target

₹1,279

(11.09% upside)

Analyst Consensus: Hold

Stock Forecasts

News

Anupam Rasayan India Transcript: Q1 26/27

Q1 FY27 total income rose 36% YoY and EBITDA grew 35%, while PAT increased 6% amid higher depreciation. Growth plans center on new product ramps, Jayhawk and the pending Bliss acquisition; full-year EBITDA margin guidance is 22%-24% consolidated.

2 months ago - Transcripts

Anupam Rasayan India Quarterly report: Q1 2027

Anupam Rasayan India has published its Q1 2027 quarterly earnings report on August 14, 2026.

2 months ago - Filings

Anupam Rasayan India Slides: Q1 2027

Anupam Rasayan India has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 14, 2026.

2 months ago - Filings

Anupam Rasayan India commercialises ETFA using flow chemistry, a global first

Anupam Rasayan India Ltd. has announced the commercialisation of ETFA (Ethyl trifluoroacetate) production through its proprietary continuous flow chemistry platform. This marks a global first in the c...

4 months ago - Business Upturn

Anupam Rasayan makes Rs 299 per share open offer for Bliss GVS Pharma

Anupam Rasayan India Limited has announced an open offer to acquire up to 2,77,26,848 fully paid-up equity shares of Bliss GVS Pharma Limited at a price of ₹299 per share.…

4 months ago - Business Upturn

Bliss GVS Pharma faces Rs 299 per share open offer from Anupam Rasayan

Bliss GVS Pharma Limited is the target of an open offer from Anupam Rasayan India Limited, which seeks to acquire up to 2,77,26,848 fully paid-up equity shares. This represents 26%…

4 months ago - Business Upturn

Anupam Rasayan India Transcript: Q4 25/26

FY26 revenue rose 65% to INR 2,384 crore, with INR 334 crore of operating cash flow and greater pharma and materials exposure. Growth plans center on acquisitions, pipeline commercialization and capacity utilization, while Bliss completion and integration remain key execution factors.

5 months ago - Transcripts

Anupam Rasayan India Annual report: Q4 2026

Anupam Rasayan India has published its Q4 2026 annual report on May 25, 2026.

5 months ago - Filings

Anupam Rasayan India Quarterly report: Q4 2026

Anupam Rasayan India has published its Q4 2026 quarterly earnings report on May 25, 2026.

5 months ago - Filings

Anupam Rasayan India Slides: Q4 2026

Anupam Rasayan India has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 25, 2026.

5 months ago - Filings

Anupam Rasayan India acquires up to 48.2% stake in Bliss GVS Pharma

Anupam Rasayan India Ltd. has announced a significant acquisition, entering into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited. The acquisition also includes ...